Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis

被引:28
|
作者
Petrasek, Jan [1 ]
Csak, Timea [1 ]
Ganz, Michal [1 ]
Szabo, Gyongyi [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA
关键词
alcoholic liver disease; alcoholic steatohepatitis; inflammasome; innate immunity; interleukin-1; beta; interleukin-1 receptor antagonist; Kupffer cells; non-alcoholic steatohepatitis; Toll-like receptors; INDUCED LIVER-INJURY; IL-1 RECEPTOR ANTAGONIST; NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTOR-4; DIET-INDUCED OBESITY; RAT KUPFFER CELLS; FATTY LIVER; INTESTINAL PERMEABILITY; HEPATIC STEATOSIS; PLASMA ENDOTOXIN;
D O I
10.1111/jgh.12020
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The similar histopathological characteristics of alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH), and the crucial role of the innate immune response in both conditions may lead to the assumption that ASH and NASH represent the same pathophysiological entities caused by different risk factors. In this review paper, we elaborate on the pathophysiological differences between these two entities and highlight the disease-specific involvement of signaling molecules downstream of the Toll-like receptor 4, and the differential mechanism by which the inflammasome contributes to ASH versus NASH. Our findings emphasize that ASH and NASH have disease-specific mechanisms and therefore represent distinct biological entities. Further studies are needed to dissect the emerging differences in pathogenesis of these two conditions.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 50 条
  • [21] Obesity and non-alcoholic steatohepatitis
    García-Monzón, C
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 117 - 123
  • [22] Drugs and non-alcoholic steatohepatitis
    Farrell, GC
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 132 - 139
  • [23] Selonsertib for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 852 - 852
  • [24] Metformin in non-alcoholic steatohepatitis
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Zoli, M
    Melchionda, N
    LANCET, 2001, 358 (9285): : 893 - 894
  • [25] Treatment of non-alcoholic steatohepatitis
    Angulo, P
    Lindor, KD
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) : 797 - 810
  • [26] Fructose and Non-Alcoholic Steatohepatitis
    Roeb, Elke
    Weiskirchen, Ralf
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [27] Saroglitazar for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 698 - 698
  • [28] Mechanisms of non-alcoholic steatohepatitis
    McClain, CJ
    Mokshagundam, PL
    Barve, SS
    Song, ZY
    Hill, DB
    Chen, T
    Deaciuc, I
    ALCOHOL, 2004, 34 (01) : 67 - 79
  • [29] Statins in Non-alcoholic Steatohepatitis
    Torres-Pena, Jose D.
    Martin-Piedra, Laura
    Fuentes-Jimenez, Francisco
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [30] Diagnosis of non-alcoholic steatohepatitis
    James, OFW
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 34 - 39